|
a metabolic disease in which the pancreas fails to produce insulin, a hormone that allows blood sugar to be absorbed by cells for proper function.
|
Author:
Yngve, Agneta
Page:
971-972
]]>
Author:
Hughes, Roger
Page:
973
]]>
Author:
Cannon, Geoffrey
Page:
974-977
]]>
Author:
Lund, Vivien *; Stockley, Lynn; Levy, Louis
Page:
978-979
]]>
Author:
Gibson, Sigrid; on behalf of the Food Standards Agency
Page:
980-988
]]>
Author:
Oddy, W H 1,2; Miller, M 1; Payne, J M 1; Serna, P 1; Bower, C I 1,3,*
Page:
989-995
]]>
Author:
Senarath, Upul 1; Dibley, Michael J 2,*+; Agho, Kingsley E 3
Page:
996-1004
]]>
Author:
Giskes, Katrina 1,2,*; Kamphuis, Carlijn BM 2; van Lenthe, Frank J 2; Kremers, Stef 3; Droomers, Mariel 4; Brug, Johannes 2
Page:
1005-1017
]]>
Author:
Granado, F *; Blazquez, S and; Olmedilla, B +
Page:
1018-1023
]]>
Author:
Cowburn, Gill *; Boxer, Anna
Page:
1024-1031
]]>
Author:
Assey, Vincent D 1,2,*; Mgoba, Celestin 1; Mlingi, Nicholaus 1; Sanga, Alfred 1; Ndossi, Godwin D 1; Greiner, Ted 2,+; Peterson, Stefan 3,4
Page:
1032-1038
]]>
Author:
Madanat, Hala N 1,2,*; Brown, Ralph B 3; Hawks, Steven R 2
Page:
1039-1046
]]>
Author:
Mamabolo, R L 1,*; Kruger, H S 1; Lennox, A 2; Monyeki, M A 2; Pienaar, A E 2; Underhay, C 2; Czlapka-Matyasik, M 1
Page:
1047-1056
]]>
Author:
Smith, Albert F 1,*; Baxter, Suzanne Domel 2; Hardin, James W 3; Guinn, Caroline H 2; Royer, Julie A 2; Litaker, Mark S 4
Page:
1057-1066
]]>
Author:
Liu, Jian 1,*; Sempos, Christopher 2
Page:
1067-1076
]]>
Author:
Silvera, Stephanie AN 1,*; Jain, Meera 2; Howe, Geoffrey R 3; Miller, Anthony B 2; Rohan, Thomas E 4
Page:
1076-1081
]]>
Author:
Hendricks, M 1,*; Beardsley, J 2; Bourne, L 3; Mzamo, B 1,3; Golden, B 2
Page:
1082-1088
]]>
Author:
Su, Dada 1; Zhao, Yun 1; Binns, Colin 1,*; Scott, Jane 2; Oddy, Wendy 1
Page:
1089-1093
]]>
Author:
Hjartaker, Anette 1,2,*,+; Andersen, Lene Frost 3; Lund, Eiliv 2
Page:
1094-1103
]]>
Author:
Knudsen, Vibeke K 1,*; Hansen, Harald S 2; Ovesen, Lars 3; Mikkelsen, Tina B 1; Olsen, Sjurour F 1
Page:
1104-1110
]]>
|
|
How Diabetic Cooking Can Save A Diabetic Person's Life?
By Sean
Patient foods are always considered to be a very unattractive term in the world of gastronomy. People tend to think that diabetic cooking is nothing but a whole bunch of restrictions and the entire cuisine is about eating all the foods that you would not even consider to be a whole square meal. This is definitely the idea that is making people cringe when they are diagnosed with diabetes. The idea on living on a frugal diet for a whole life makes them more miserable than the disease itself can make them.
There are several myths surrounding food recipes. Here I try to dispel some of these myths.
Myth # 1 diabetic cooking is always bland and boring.
Just because you are not allowed to eat certain foods when you have does not mean that the foods will be bland and boring. You can create gourmet delights with the foods that you are allowed to eat, and that's a fact. You can try different avenues of cooking that are healthier. For instance, you can roast
your meat instead of cooking it in oil. You can replace red meats with white meats. There are several such things that you can do to make your diet interesting.
Myth # 2 diabetic diet means never having to eat favorite foods ever again.
While it is true that you won't be exactly allowed to gorge on your favorite foods when you have diabetes, it does not mean that you will never be able to eat them anymore. You must understand that the whole idea of a diabetic diet is to allow the foods to metabolize properly. If you are eating your favorite food, there's no harm done if that food can get out of your system after digestion. Patient food methods tell you how to balance foods so that none of them accumulate in your system. Like, if you eat a dessert, you can balance it with some bitter food later on that will allow the dessert to be out of your system.
Myth # 3 health cooking is synthetic and expensive.
People have this misconception because of the sugar-free substitutes that diabetic people are told to use. But you must know that these substitutes are not a necessary part of the diet. You can do without them. In fact, you can do without the sweet taste altogether. When you are diabetic, it is a good time to experiment with different kinds of tastes and flavors. Any good diabetic cookbook will tell you several ways of doing this. Actually, cooking is much cheaper than normal cooking, because of the economical cooking methods used.
Here are some more diabetes articles...
Diabetes And Exercise
By Randall
Exercise will have a positive effect on diabetes type II while improving insulin sensitivity while type I cannot be controlled be an exercise Read more...
|
Doctors Formula Liquid Vitamins - Liquid Glucosamine - Liquid Vitamin Supplements 582
By robbyknobby
Liquid life supplements check all the essential nutrients required by your body. This appendage contains numerous , and vitamins. Liquid life contains minerals derived from the Read more...
|
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
<b>Condition</b>: Type 2 Diabetes<br/><b>Interventions</b>: Drug: Dapagliflozin; Drug: Dapagliflozin; Drug: Placebo<br/><b>Sponsors</b>: Bristol-Myers Squibb; AstraZeneca<br/><b>Not yet recruiting</b> - verified September 2010
Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes
<b>Condition</b>: Type II Diabetes Mellitus<br/><b>Intervention</b>: Drug: CM3.1-AC100<br/><b>Sponsor</b>: CellMed AG, A Subsidiary of Biocompatibles International plc.<br/><b>Recruiting</b> - verified September 2010
Euglycemic Clamp Dose-response Study Comparing Insulin Glargine U300 With Lantus® U100
<b>Condition</b>: Type 1 Diabetes Mellitus<br/><b>Interventions</b>: Drug: Insulin glargine (HOE901); Drug: Insulin glargine (HOE901)<br/><b>Sponsor</b>: Sanofi-Aventis<br/><b>Recruiting</b> - verified September 2010
Efficacy of Adding Sitagliptin or Pioglitazone to T2DM Insufficiently Controlled With Metformin and Sulfonylurea
<b>Condition</b>: Type 2 Diabetes<br/><b>Interventions</b>: Drug: Sitagliptin; Drug: pioglitazone<br/><b>Sponsor</b>: Mackay Memorial Hospital<br/><b>Recruiting</b> - verified September 2010
Benefit/Risk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 Diabetes
<b>Condition</b>: Diabetes Mellitus, Type 1<br/><b>Interventions</b>: Drug: HUMAN INSULIN (BIOSYNTHETIC); Drug: Insuplant<br/><b>Sponsor</b>: Sanofi-Aventis<br/><b>Not yet recruiting</b> - verified September 2010
Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study
<b>Condition</b>: Diabetes Mellitus, Type 2<br/><b>Interventions</b>: Drug: Placebo; Drug: Linagliptin<br/><b>Sponsor</b>: Boehringer Ingelheim Pharmaceuticals<br/><b>Not yet recruiting</b> - verified September 2010
Effect of Formoterol on the Counterregulatory Hormonal Response to Hypoglycemia
<b>Condition</b>: Type 1 Diabetes<br/><b>Intervention</b>: Drug: Formoterol<br/><b>Sponsors</b>: Yale University; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)<br/><b>Recruiting</b> - verified September 2010
An Open-randomized, Balanced, Crossover Bioequivalence Study to Compare One MR Tablet of 60 mg Gliclazide and Two MR Tablets of 30 mg Gliclazide in Healthy Subjects
<b>Conditions</b>: Hyperglycemia; Diabetes<br/><b>Intervention</b>: <br/><b>Sponsor</b>: Taipei Medical University WanFang Hospital<br/><b>Recruiting</b> - verified September 2010
Insulin Administration Plus a Telemedicine System (Diabetes Interactive Diary - DID) vs Insulin Plus Common Practice
<b>Condition</b>: Type 1 Diabetes<br/><b>Intervention</b>: Device: Diabetes Interactive Diary (DID)<br/><b>Sponsors</b>: Consorzio Mario Negri Sud; Sanofi-Aventis; LifeScan<br/><b>Recruiting</b> - verified September 2010
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 1 Diabetes Mellitus
<b>Condition</b>: Diabetes Mellitus, Type 1<br/><b>Intervention</b>: Drug: Insulin LISPRO<br/><b>Sponsor</b>: Halozyme Therapeutics<br/><b>Recruiting</b> - verified September 2010
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus
<b>Condition</b>: Diabetes Mellitus, Type II<br/><b>Intervention</b>: Drug: Insulin LISPRO<br/><b>Sponsor</b>: Halozyme Therapeutics<br/><b>Recruiting</b> - verified September 2010
Anterior and Posterior Segment Vascular Changes Following Laser and Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Diabetic Retinopathy
<b>Condition</b>: Diabetic Macular Edema<br/><b>Intervention</b>: <br/><b>Sponsors</b>: University of Toronto; Juvenile Diabetes Research Foundation<br/><b>Recruiting</b> - verified September 2010
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes: An Extension Trial to NN1250-3579
<b>Condition</b>: Diabetes Mellitus, Type 2<br/><b>Interventions</b>: Drug: NN1250; Drug: insulin glargine<br/><b>Sponsor</b>: Novo Nordisk<br/><b>Not yet recruiting</b> - verified August 2010
Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With or Without Metformin and With/Without Pioglitazone in Type 2 Diabetes: An Extension Trial to NN1250-3582
<b>Condition</b>: Diabetes Mellitus, Type 2<br/><b>Interventions</b>: Drug: NN1250; Drug: insulin glargine; Drug: insulin aspart<br/><b>Sponsor</b>: Novo Nordisk<br/><b>Recruiting</b> - verified September 2010
BI 10773 Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus
<b>Condition</b>: Diabetes Mellitus, Type 2<br/><b>Interventions</b>: Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: Placebo<br/><b>Sponsor</b>: Boehringer Ingelheim Pharmaceuticals<br/><b>Not yet recruiting</b> - verified August 2010
Risk Factors for Low Lymphocyte Count in Patients With Type 2 Diabetes
<b>Condition</b>: Diabetes Mellitus, Type 2<br/><b>Intervention</b>: <br/><b>Sponsors</b>: Bristol-Myers Squibb; AstraZeneca<br/><b>Active, not recruiting</b> - verified August 2010
A Study of OPC-262 in Patients With Type 2 Diabetes
<b>Condition</b>: Diabetes, Type 2<br/><b>Intervention</b>: Drug: OPC-262<br/><b>Sponsor</b>: Otsuka Pharmaceutical Co., Ltd.<br/><b>Recruiting</b> - verified August 2010
Clinical Trial Evaluating the Efficacy and Safety of Technosphere Insulin Inhalation Power Using the Gen2 Inhaler
<b>Condition</b>: Type 2 Diabetes<br/><b>Interventions</b>: Drug: Technosphere Insulin; Drug: Insulin Aspart; Drug: Glargine<br/><b>Sponsor</b>: Mannkind Corporation<br/><b>Not yet recruiting</b> - verified September 2010
Glycemic Holter Study (Continuous Glucose Monitoring) -
<b>Condition</b>: Type 2 Diabetes Mellitus<br/><b>Interventions</b>: Drug: Vildagliptin; Drug: Sitagliptin<br/><b>Sponsor</b>: Novartis<br/><b>Recruiting</b> - verified August 2010
Malignancy Meta Analysis for BRL49653
<b>Condition</b>: Diabetes Mellitus, Type 2<br/><b>Intervention</b>: Drug: allocation of treatment with metformin or rosiglitazone<br/><b>Sponsor</b>: GlaxoSmithKline<br/><b>Completed</b> - verified September 2010
Psychosocial Interventions in the Treatment of Youth With Type 1 Diabetes Mellitus
<b>Condition</b>: Diabetes Mellitus<br/><b>Intervention</b>: Behavioral: psychosocial intervention<br/><b>Sponsor</b>: Assaf-Harofeh Medical Center<br/><b>Recruiting</b> - verified August 2010
Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)
<b>Condition</b>: Type 2 Diabetes Mellitus<br/><b>Intervention</b>: Drug: vildagliptin/metformin<br/><b>Sponsor</b>: Novartis<br/><b>Recruiting</b> - verified September 2010
Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)
<b>Condition</b>: Diabetes Mellitus<br/><b>Interventions</b>: Drug: saxagliptin; Drug: metformin XR; Drug: saxagliptin + metformin XR (FDC tablet)<br/><b>Sponsor</b>: Bristol-Myers Squibb<br/><b>Completed</b> - verified August 2010
Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR
<b>Condition</b>: Diabetes Mellitus<br/><b>Interventions</b>: Drug: saxagliptin; Drug: Glucophage XR; Drug: saxagliptin + metformin XR (FDC tablet)<br/><b>Sponsor</b>: Bristol-Myers Squibb<br/><b>Completed</b> - verified August 2010
A Study in Patients With Type 2 Diabetes Mellitus (AWARD-4)
<b>Condition</b>: Diabetes Mellitus, Type 2<br/><b>Interventions</b>: Drug: Insulin Glargine; Drug: LY2189266<br/><b>Sponsor</b>: Eli Lilly and Company<br/><b>Not yet recruiting</b> - verified August 2010
Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes: An Extension Trial to NN1250-3585
<b>Condition</b>: Diabetes Mellitus, Type 1<br/><b>Interventions</b>: Drug: NN1250; Drug: insulin detemir (Levemir®); Drug: insulin aspart<br/><b>Sponsor</b>: Novo Nordisk<br/><b>Recruiting</b> - verified September 2010
Exploratory Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus and Secondary Hypogonadism or Adult-Onset Idiopathic Hypogonadotropic Hypogonadism
<b>Conditions</b>: Type 2 Diabetes Mellitus; Secondary Hypogonadism<br/><b>Interventions</b>: Drug: Placebo; Drug: enclomiphene citrate<br/><b>Sponsor</b>: Repros Therapeutics Inc.<br/><b>Not yet recruiting</b> - verified September 2010
Dietary Intervention With Shop Model - SHOPUS
<b>Condition</b>: Obesity<br/><b>Intervention</b>: Behavioral: Dietary intervention<br/><b>Sponsor</b>: University of Copenhagen<br/><b>Recruiting</b> - verified July 2010
Adipose Tissue Gene Expression Profiles in Women With Polycystic Ovary Syndrome (PCOS) Versus Controls
<b>Condition</b>: Polycystic Ovary Syndrome<br/><b>Intervention</b>: <br/><b>Sponsors</b>: The Adelaide and Meath Hospital; University College Dublin<br/><b>Completed</b> - verified July 2008
Cardiovascular Risk Markers in Polycystic Ovary Syndrome (PCOS)
<b>Condition</b>: Polycystic Ovary Syndrome<br/><b>Intervention</b>: <br/><b>Sponsors</b>: The Adelaide and Meath Hospital; University College Dublin<br/><b>Completed</b> - verified July 2008
A 12-week, Multicentric Study to Evaluate the Safety and Efficacy of Bisoprolol in Diabetic and Hypertensive Filipinos
<b>Condition</b>: Hypertension<br/><b>Intervention</b>: Drug: Bisoprolole<br/><b>Sponsor</b>: Merck KGaA<br/><b>Recruiting</b> - verified August 2010
Safety and Efficacy of Chlorthalidone + Amiloride to Elderly Patients Treatment With Arterial Hypertension
<b>Condition</b>: Arterial Hypertension<br/><b>Interventions</b>: Drug: Chlorthalidone 25 mg + amiloride hydrochloride 5 mg; Drug: Higroton® Laboratório Novartis<br/><b>Sponsor</b>: Eurofarma Laboratorios Ltda<br/><b>Not yet recruiting</b> - verified August 2010
Follow-up to Adult Height of a Cohort of Subjects Born Small for the Gestational Age and Treated With Growth Hormone
<b>Condition</b>: Infant, Small for Gestational Age<br/><b>Intervention</b>: <br/><b>Sponsor</b>: Merck KGaA<br/><b>Enrolling by invitation</b> - verified September 2010
|
|
|
Resources |
Diabetes And Vision Loss: Take Action Now
By John
Before the 1970's, the general population did not consider diabetes to be a major health concern, let alone realize the adverse impacts diabetes would Read more...
|
|
|
